MedCity News January 2, 2026
Microdosing won’t be the right choice for everyone. But for many patients, it’s already proving to be the difference between quitting obesity treatment early and making lasting progress.
Over the past few years, GLP-1 medications like Ozempic and Wegovy have reshaped the conversation around weight loss and metabolic health. For many, these medications have been life-changing. Yet, despite their transformative potential, a troubling pattern has emerged. Many patients are finding that they are being prescribed medications without taking into account their different metabolisms and needs. This one-size-fits-all approach is failing patients, and the consequences are impossible to ignore.
The standardization trap
The statistics say it all: half of U.S. patients using GLP-1s for obesity care discontinued use within the...
Today's Sponsors
Today's Sponsor